Nrxp investors have opportunity to lead nrx pharmaceuticals, inc. securities fraud lawsuit

Los angeles, feb. 22, 2022 /prnewswire/ -- glancy prongay & murray llp ("gpm") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against nrx pharmaceuticals, inc. ("nrx" or the "company") (nasdaq: nrxp). class period: june 1, 2021 – november 4, 2021 lead plaintiff deadline: march 21, 2022 if you wish to serve as lead plaintiff of the nrx lawsuit, you can submit your contact information at www.glancylaw.com/cases/nrx-pharmaceuticals-inc/.
NRXP Ratings Summary
NRXP Quant Ranking